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The Precision Medicine Initiative aims to advance Medicine from “one-size-fits-all” 
treatments to more individualized approaches. Clinical trials evaluate treatments by 
analyzing average outcomes, and thus risk overlooking potential differences in treatment 
effect among different subsets of the study population. The use of multivariate models 
has been proposed as a way to identify heterogeneity of treatment effect and to determine 
patients’ individualized treatment risks and benefits. 
 
We analyzed the Randomized Evaluation of Long-Term Anticoagulation Therapy 
(RELY) trial of dabigatran versus warfarin in patients with atrial fibrillation, to determine 
if the application of multivariate predictive models could demonstrate heterogeneity of 
treatment effect among the study population. We developed two models to predict 
patients’ risk of stroke or systemic embolism and risk of major bleeding if treated with 
dabigatran or warfarin. We then applied these models to the individual patients in the RE-
LY trial, and determined patients difference in risk if treated with dabigatran versus 
warfarin. Individual difference in stroke risk for dabigatran 110mg and 150mg versus 
warfarin was -0.78% ± 0.95% and -1.32% ± 1.31% and the difference in major bleeding 
risk was -1.12% ± 1.44% and -0.41% ± 2.39%, respectively. 
 
These findings demonstrate heterogeneity of treatment effect in the RE-LY trial, and the 
ability of multivariate risk models to identify distinct treatment risks for individual 
patients. Such models could be used in clinical practice provide patients and clinicians 
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In 1970, the famous Boston Red Sox hitter Ted Williams, known best for his 
extraordinary and yet untouched record .408 batting average, published “the science of 
hitting,” a book to teach boys and girls across America how to consistently hit a 
baseball.a He demonstrated the first rule of hitting, “get a good ball to hit,” through an 
illustration of the strike zone that showed his personal batting average for balls thrown in 
different locations (1). 
 







The purpose of this diagram was to show that every individual should calculate their own 
unique batting average for pitches in different locations, so they could swing at those 
pitches where they had a high average, and avoid pitches where they didn’t hit as well. 
The notion that one size doesn’t fit all, and that unique statistical profiles can inform 
individualized hitting styles, was one of the earliest and most provocative displays of the 
power of infusing the art of hitting, with science. 
 
In his 2015 State of the Union Address, President Barack Obama launched the Precision 
Medicine Initiative, with the mission of advancing Medicine from “on-size-fits-all” 
treatments to more individualized approaches. Underlying this initiative, is the premise 
that while treatments are generally developed for the “average patient,” most patients are 
not in fact, average (2). The urgency of this initiative is brought on by a recognition that 
Medicine is in an age of increasing availability of data from sources such as genomic 
profiles, advanced diagnostic imaging, wearable devices, and clinical records in 
electronic health records. This data presents the opportunity to create unique patient 
profiles that can guide personalized treatment decisions, and to achieve an age of 
“precision medicine.”(3) The use of such profiles has the potential to enhance both the 
science and the art of Medicine. In this Thesis, I evaluate the potential to use multivariate 
predictive risk models, to create individualized patient treatment risk and benefit profiles, 








The application of traditional randomized trials to clinical practice and the limitation of 
subgroup analyses 
 
Randomized controlled trials are the gold standard for evaluating the effectiveness of 
medical treatments. These trials are designed such that their results are generalizable, and 
can inform treatment decision for broad populations of patients. Results are usually 
reported as an overall treatment effect, defined as the average effect observed among all 
enrolled patients. However, a major limitation of this practice, is that the average effect 
may be heavily influenced by a subset of the population that has large treatment effect, 
even if much of the population saw no treatment effect (4).  In practice, clinicians need to 
figure out how to apply these average results to individual patients, each with their own 
distinct comorbidities and demographics, and consequently, potentially different risks. 
Clinical investigators commonly address this challenge by publishing subgroup analyses, 
through which patients are categorized according to an individual variable, and results are 
published for each patient subgroup. For example, a given trial might publish the results 
of an antihypertensive for men and for women, for people over the age of 65 and people 
under the age of 65, or people with diabetes and people without diabetes.  
 
While these subgroup analyses can be helpful, they face a number of challenges. First, 
they have statistical limitations. They often have very limited statistical power and 
consequently are subject to false negatives. Additionally, as the number of subgroups 
increases, false positives will increase and reliability will subsequently decrease. Burke et 






of ordering diagnostic testing for patients with and without an indication. Following 
Bayes’ rule, positive findings in the group without an indication for testing, are more 
likely to be false positives, than if they were found in the group who had an indication. 
Similarly, adding numerous subgroup analyses to a research study, without strong 
hypotheses for each analysis, is likely to lead to false positive findings (5). Last, 
subgroup analyses, are limited to analyzing populations by categorical variables, and are 
unable to take full advantage of continuous data such as age or blood pressure (4). 
 
Second, subgroup analyses can pose dilemmas for individual treatment decision making, 
especially given their usual reporting of hazard ratios, or relative risk reduction without 
corresponding information about pre-treatment risk, or absolute risk reduction. For 
example, suppose a clinical trial compared anticoagulants A and B for stroke prevention 
in atrial fibrillation, and found drug A to be associated with lower rates of stroke for 
people over the age of 65, and drug B to be associated with lower rates of stroke for 
people with diabetes. In such a scenario, how do a 70-year-old diabetic patient and her 
physician determine which medication would be best? To answer this question, the 
physician and the patient need to know whether the absolute benefit of stroke prevention 
of drug A is larger than the absolute benefit of drug B. And to determine this absolute 
benefit, we need to know the relative risk reduction with drug A and drug B, and the pre-
treatment risk of their populations. For example, if the 10-year pre-treatment risk of 
stroke in the 65 years and older population is 10%, and drug A showed a 50% reduction 
in stroke, then the absolute decrease in stroke risk from using drug A is 5%. On the other 






similar 50% risk reduction in using drug B, translates into a 0.5% absolute reduction in 
risk. In this case, the patient and clinician would likely choose drug A given the absolute 
risk reduction of 5% compared to the alternative absolute risk reduction of 0.5% (5). 
 
For simplicity, the scenario above compares the benefits of two drugs. However, also 
common that patients and clinicians need to weigh the benefits of an individual drug 
versus the risks of that same drug. For example, patients considering anticoagulation 
generally need to weigh the benefit of stroke or embolus prevention against the risk of 
major bleeding. In these situations, the absolute risk of the medical event trying to be 
prevented (the benefit) needs to be compared to the absolute risk of an adverse event (the 
risk). This decision-making exercise will identify patients for whom the benefit of a given 
treatment far outweigh the risks, as well as patients for whom the risks far outweigh the 
benefits. If, for simplicity, we assume the absolute risk of adverse events is the same 
across all patients, then this decision is based purely on the degree of benefit each patient 
will realize. And if the relative benefit is the same for all patients, then their absolute 
benefit from the treatment is simply a function of their pre-treatment risk (4). For 
example, an anticoagulant that carries an identical absolute risk of bleeding for all 
patients, and carries an identical relative risk reduction in stroke for all patients, might 
only be appropriate for patients who have a very high pre-treatment risk of stroke, as they 
will see a very large absolute benefit from treatment. For those patients who have a very 
small pre-treatment risk of stroke, the absolute benefit would be smaller, and might not 
outweigh the absolute risk. Thus, one of the simplest ways to determine if somebody 






treatment risk, in order to estimate the potential absolute benefit of treatment. Such is the 
rationale behind the CHADS and CHADSVASC2 scores to identify patients with the 
highest pre-treatment risk, and therefore the greatest potential benefit from 
anticoagulation. A similar exercise can be done to estimate the pre-treatment risk of an 
adverse event, and thus to predict the absolute risk of the adverse event occurring with 
treatment (4). 
 
However, the absolute benefit or risk of a treatment is also a function of relative risk. And 
relative risk is not necessarily uniform across a population. There may be specific groups 
of patients who have a particularly high relative risk or a particularly high relative benefit 
associated with a given treatment. The importance of identifying these different subsets 
of patients, highlights another limitation of subgroup analyses. 
 
The third challenge facing subgroup analyses the difficulty in defining a subgroup. In 
some cases, subgroup definitions are clear. For example, it is known that the HER2 
receptor plays a key role in the mechanism of action of Trastuzumab, and it would thus 
make sense to build patient subgroups based on the genetic HER2 characteristic. In such 
scenarios, in which a subgroup characteristic is clearly a part of a drug’s mechanism of 
action, the use of subgroup analyses are appropriate (4). However, the appropriate 
definition of a subgroup is not always as clear, and as a result, the usefulness of subgroup 
analyses is limited. For example, in a study of an anticoagulant, it is difficult to determine 
whether a subgroup age cutoff should be 65 versus 70 versus 75. It is possible for 






diabetes, have a uniquely great risk reduction from using drug A, or that those who are 
below 40 years old and do not have diabetes have a particularly strong risk of bleeding. 
These findings however, would be missed from a clinical trial that made one subgroup 
based on age greater than 65, and another subgroup based on the presence of diabetes. A 
similar scenario was seen in the GUSTO trial, which in 1993 found that patients 
benefited from tPA relative to streptokinase for acute myocardial infarction, and in the 
subgroup analysis did not find the benefit to be limited to any specific population (6). 
However, in 2002, Kent et al re-analyzed the GUSTO data using newly developed risk-
stratification tools, to predict those patients who would benefit most from treatment, and 
found that nearly all of the treatment benefits were seen among approximately 50% of 
patients who were predicted to benefit the most (7). This implied that the approximately 
50% of patients with the lower predicted benefits, saw little to no benefit from treatment, 
and given that they still faced the drug risk of bleeding, should not be given the drug in 
clinical practice (4). 
 
Given that subgroup analyses are subject to statistical limitations, conflicting relative risk 
information from different subgroups, and sub-optimal definition of subgroups, a number 











Multivariate Risk Prediction Models 
 
Netflix, one of the most popular users of multivariate risk prediction models, is well-
known for its ability to successfully provide individual subscribers with a personalized 
list of “shows you might like.” Netflix could decide which show to recommend to a given 
subscriber by looking at their entire subscriber base and studying the ratings of “The 
Crown” versus “Mad Men,” and then recommend one of these shows to all subscribers 
accordingly. Or, they could make a recommendation to a subscriber based on whether or 
not they were over or under the age of 65, study “The Crown” versus “Mad Men” for 
these two age based subgroups, and recommend one of the shows accordingly. However, 
instead of relying on broad studies to predict subscriber preferences, Netflix has 
developed multivariate risk prediction models, that make use of individualized 
information captured from every subscriber, such as the genre of shows they watch, and 
the time of day they watch them, and the speed with which they finish them. With this 
information, Netflix can develop a multivariate predictive risk model that can classify 
that subscriber, and precisely predict the which show they will enjoy watching next.  
 
Given the massive amount of data collected from clinical research, genetic and clinical 
registries, wearable devices, and electronic health records, there is great potential for 
multivariate risk prediction models in healthcare to identify individual patients who 
would benefit from specific therapeutics and specific doses. While multivariate models 
are just one of many strategies to learn from big data, they are an important step towards 






office, where the physical activity data from his wearable watch, his daily glucometer 
readings, his HbA1C from the lab, his other medications from the pharmacy, and 
information about his other comorbidities, his weight and vital signs and his genetic 
profile, are all fed into an algorithm that highlights his precise individual risks and 
benefits from using metformin versus pioglitazone (8).  
 
There should still be a role for “one-size-fits-all” treatment approaches for diseases that 
are highly prevalent, and have treatments that are highly effective, with minimal risk (9). 
However, for diseases in which multiple treatment options provide different treatment 
benefits and different risks of significant adverse events, a precision approach is 
warranted. 
 
The multivariate risk prediction model has proposed as a method through which the 
variety of baseline and outcome data, categorical and continuous, can be used to predict 
patients’ individual risks and benefits with a given treatment (4). Multivariate models are 
generally produced by developing a multivariable linear regression model, and refining 
the model, by adding or removing variables, in order to strengthen its predictive 
capabilities (10). Such a model, will produce a risk formula in the format of Y (risk) = b0 
+ X1b1 + X2b2 where b0 is the model’s intercept, b1-2 are coefficients 1 and 2, and X1-2 are 
the patients variables. For continuous variables, the value of the variable is entered in the 
model. For categorical variables, the value of 1 or 0 is entered in the model, depending on 







To test the theory that multivariate risk models can improve clinical research, and 
identify a heterogeneity of treatment effect, recent studies have applied new multivariate 
risk prediction models to completed clinical trials. Salisbury et al assessed the TRITON-
TIMI-38 trial which compared prasugrel v. clopidogrel, and developed a multivariate risk 
prediction model to determine whether there was heterogeneity of treatment effect, not 
seen in the original trial analysis. They found significant heterogeneity in the both the 
risks and benefits of clopidogrel and prasugrel for different patients (11). Kernan et al 
similarly re-analyzed the IRIS trial of pioglitazone after TIA and stroke, and using two 
risk models developed from the IRIS data, and one external model, also found 
heterogeneity (12). 
 
Our study applies a similar principle to the RE-LY trial of Warfarin versus Dabigatran for 
stroke prevention in patients with atrial fibrillation in order to assess the extent to which 















The RE-LY Trial 
 
Across the United States, atrial fibrillation (AF) affects 2.7-6.1 million people, and its 
prevalence is expected to increase to 5.6-12 million by 2050 (13). AF is a cardiac 
arrhythmia, described clinically as an irregularly irregular heart beat due to irregular 
electrical conduction from the sinoatrial node. This irregular heart rhythm impedes the 
regular rhythmic output of blood from the heart, and subsequent stasis of blood can lead 
to development of blood clots in the left atrial appendage. These clots can dislodge, and 
emboli can enter the cerebral vasculature, and cause a stroke. Due to this 
pathophysiology, people with AF have a 5 times increased risk for stroke (14).  
 
To prevent stroke, AF is generally controlled with rate control and anticoagulation. 
Anticoagulation with warfarin, an oral vitamin K antagonist, has historically been the 
mainstay of treatment, but given the development of Novel Oral Anticoagulants 
(NOACs), there are now more options for anticoagulation. 
 
While warfarin is an effective treatment for AF, its administration carries substantial 
lifestyle burdens that can decrease patients’ quality of life and decrease adherence. First, 
patients taking warfarin cannot eat foods that have significant amounts of vitamin K such 
as spinach or kale, as warfarin’s mechanism of action is to antagonize vitamin K. Second, 
patients who take warfarin need to have their blood INR monitored through regular blood 






and INR, that is sufficient to prevent stroke, but not too high as to increase risk of 
hemorrhage. 
 
The development of non-vitamin K oral anticoagulants, the anti-X inhibitors apixaban 
and rivaroxaban and the direct thrombin inhibitor dabigatran, were developed as 
attractive alternative anticoagulants to warfarin, as they reduce the burden of dietary 
restrictions and need for frequent blood monitoring. The lifestyle benefits of these 
medications however, need to be weighed against their clinical effectiveness, and 
numerous trials have compared the non-vitamin K oral anticoagulants versus warfarin for 



















Statement of Purpose and Hypothesis 
 
Our study focuses on the RE-LY trial which compared warfarin versus dabigatran in AF 
for the prevention of stroke (15). The RE-LY trial, conducted in 2009, included 18,113 
patients with AF who were deemed to be at increased risk of stroke. This increased risk 
of stroke was defined by factors such as a history stroke or Transient Ischemic Attack, 
age or the presence of diabetes mellitus. Exclusion criteria included patients with an 
increased risk for hemorrhage, a recent or severe stroke and active liver disease (15). 
Patients were randomized to receive either warfarin, dabigatran 110mg BID or dabigatran 
150mg BID. Patients were blinded to their dose of dabigatran, however, were not blinded 
to receiving warfarin, as blood INR needed to be monitored and warfarin doses adjusted 
in order to maintain an INR of 2.0 to 3.0. Patients were assessed for two primary 
outcomes: the presence of stroke or systemic embolism, and the presence of major 
bleeding. Other outcomes included myocardial infarction, pulmonary embolism and GI 
bleeding. The study concluded after 5 years, and found the annual rate of stroke to be 
1.69% for warfarin, 1.53% for dabigatran 110mg and 1.11% for dabigatran. The annual 
rate of major bleeding was 3.36% for warfarin, 2.71% for dabigatran 110mg and 3.11% 
for dabigatran 150mg. The analysis demonstrated that dabigatran 110mg was associated 
with similar rates of stroke and systemic embolism compared to warfarin, and a 
significantly lower rate of bleeding. Dabigatran 150mg BID was associated with lower 
rates of stroke and systemic embolism than warfarin, and a similar rate of bleeding. 








While the RE-LY trial subgroup analyses did not reveal significant differences in 
treatment effect, we sought to determine whether an analysis of the data with multivariate 
risk models would reveal heterogeneity of treatment effect (15). Using the RE-LY data, 
we developed two multivariate predictive risk models and assessed individual patients’ 
risks of stroke or systemic embolism and their risk of bleeding, if they were treated 
warfarin, dabigatran 110mg BID or dabigatran 150mg BID. We then sought to determine 
whether there were differences individual patients’ predicted risks and benefits with each 
treatment.  
 
The hypothesis of this analysis, is that there is significant heterogeneity of treatment 
effect with dabigatran versus warfarin, regarding the risk of stroke or systemic embolism, 
and the risk of major bleeding among the RE-LY population. This hypothesis is tested 
through the development of a multivariate model, and the subsequent application of that 
model to the RE-LY data to assess the degree of heterogeneity of treatment among the 
RE-LY population. 
 
The presence of such a heterogeneity of treatment effect would demonstrate the need to 
use such a multivariate predictive risk models to aid in day to day clinical decisions 
regarding warfarin versus different doses of dabigatran for stroke prevention in AF, and 












The RE-LY trial included 18,113 patients with AF who were at increased risk for stroke 
(15). Over the 2-year study period, patients were given either warfarin at a titrated dose to 
achieve an INR of 2.0-3.0, dabigatran 110mg twice a day, or dabigatran 150mg twice a 
day. Patients were regularly monitored for the presence of the primary outcomes of stroke 
or systemic embolism or major bleeding, as well as for secondary outcomes including 
pulmonary embolism, myocardial infarction and gastrointestinal bleeding. To be included 
in the study, patients were required to have a documented history of AF in the past 6 
months, as well as an increased risk of stroke, evidenced by a history of stroke or 
Transient Ischemic Attack, NYHA class II heart failure symptoms, reduced Left 
Ventricular Ejection Fraction, age greater than 75, or age 65-74 and the presence of 
hypertension, coronary artery disease or diabetes mellitus. Patients were excluded from 
the study if they had an increased risk of hemorrhage, a stroke within the past 15 days, a 
severe stroke in the past 6 months, a severe heart valve disorder, pregnancy, active liver 
disease or low creatinine clearance (15). Our study includes all patients who were 
included in the RE-LY trial and completed a 2-year course of warfarin, dabigatran 110mg 











The primary outcomes of both the RE-LY trial, and this study are stroke or systemic 
embolism and major bleeding, representing the major benefits and risks of 




Using the data from the RE-LY trial, we developed two multivariate predictive risk 
models for the two primary outcomes of stroke or systemic embolism and major 
hemorrhage. Our models were built on the methodological framework developed by 
Salisbury et al in their analysis of the TRITON-TIMI-38 study data (11). To construct 
each model, we fit a multivariable linear regression model using all variables that we 
deemed to be potentially relevant to the outcomes, based on prior research as well as the 
clinical experience of the authors. We then worked to minimize the number of variables 
in the model in order to make the models easier to use in the clinical setting. We used the 
Harrell backwards selection method to the models, to remove variables sequentially, until 
all variables retained in the model had at least a 5% contribution to the model’s predictive 
capacity (10). The included and excluded variables, and the order in which they were 
excluded are listed in Table 2, with their corresponding degree of contribution to the 
model. For each model, we calculated the discrimination (c-statistic) and calibration 
(Hosmer-Lemeshow, and used restricted cubic splines to assess the assumption that the 






To assess for heterogeneity of the benefits and risks of each treatment, we applied the risk 
models to every patient in the RE-LY trial, first assuming they were treated with 
warfarin, a second time assuming they were treated with dabigatran 110mg, and a third 
time assuming they were treated with dabigatran 150mg. To characterize the population-
level heterogeneity of treatment effect, we determined for each treatment, the mean risk 
and standard deviation of stroke or systemic embolism and the mean risk of major 
hemorrhage. To characterize the individual-level heterogeneity of treatment effect, we 
calculated the absolute difference in risk or benefit between warfarin and dabigatran 
110mg, and warfarin and dabigatran 150mg. Specifically, the absolute difference in the 
risk of stroke or systemic embolism was calculated as each patients’ risk if they were 
treated with dabigatran 110mg minus their risk if they were treated with warfarin, and as 
their risk if they were treated with dabigatran 150mg minus their risk if they were treated 
with warfarin. Similarly, the absolute difference in the risk of major hemorrhage is 
calculated as each individual’s risk of major hemorrhage with dabigatran 110mg minus 
their risk with warfarin, and their risk with dabigatran 150mg minus their risk with 
warfarin. We report a density plot to demonstrate the range of absolute differences 
between dabigatran 110mg and warfarin, and dabigatran 150mg and warfarin.  
 
We report categorical variables as frequencies, and continuous variables as medians with 
interquartile ranges. 
 






The initial statistical model was based on the model described by Salisbury et al, and the 
model development was conducted by Sophie Tang, at Saint Luke’s Mid America Heart 
Institute, with a research group led by Dr. John Spertus (11). Dr. Nihar Desai and I 
worked closely together to interpret the statistical output for clinical relevance, and 
worked closely with Sophie Tang to determine the data output most relevant to the 
hypothesis and project.  
 
For example, I proposed that we create “mock patients” based on the model, and worked 
with Dr. Desai and Sophie Tang to develop a risk calculator, based on the model output. 
And using this model, I created the mock patients that are included in the thesis as part of 




















A total of 18,040 patients were included in the analysis, 5,983 of whom were assigned to 
dabigatran 110mg in the RE-LY trial, 6,059 of whom were assigned to dabigatran 
150mg, and 5,998 of whom were assigned to warfarin. The median age was 71.4 ± 8.6 
and 3.6% of participants were male. The ethnicity of the subjects, was 15.9% Asian, 
1.0% Black, 70.0% White, and 13.1% Other. The distribution of AF types of paroxysmal, 
permanent and persistent were 32.8%, 35.2% and 32.0%, respectively. Baseline 
characteristics included heart failure (32.0%), hypertension (78.8%), diabetes mellitus 
(23.3%) and stroke/systemic embolism/TIA (21.8%). As seen in Table 1, demographic 


















Table 1: Baseline Characteristics 
  
Treatment Pattern Label Total 
     P-
Value 
Dabigatran 110mg BID 
n = 5983 
Dabigatran 150mg BID 
n = 6059 
Warfarin 
n = 5998 n = 18040 
Age     0.693 
    Mean ± SD 71.3 ± 8.6 71.4 ± 8.7 71.5 ± 8.5 71.4 ± 8.6  
    Median (IQR) 72.0 (67.0, 77.0) 72.0 (67.0, 78.0) 72.0 (67.0, 77.0) 72.0 (67.0, 77.0)  
Age Grouping     0.121 
   <40 21 (0.4%) 26 (0.4%) 12 (0.2%) 59 (0.3%)  
   40<= and <50 99 (1.7%) 86 (1.4%) 89 (1.5%) 274 (1.5%)  
   50<= and <65 873 (14.6%) 916 (15.1%) 849 (14.2%) 2638 (14.6%)  
   65<= and <75 2655 (44.4%) 2574 (42.5%) 2635 (43.9%) 7864 (43.6%)  
   >=75 2335 (39.0%) 2457 (40.6%) 2413 (40.2%) 7205 (39.9%)  
Sex     0.323 
  Female 2130 (35.6%) 2228 (36.8%) 2202 (36.7%) 6560 (36.4%)  
Ethnicity     0.871 
  Asian 948 (15.8%) 961 (15.9%) 955 (15.9%) 2864 (15.9%)  
  Black 51 (0.9%) 57 (0.9%) 66 (1.1%) 174 (1.0%)  
  White 4191 (70.0%) 4258 (70.3%) 4181 (69.7%) 12630 (70.0%)  
  Other 793 (13.3%) 783 (12.9%) 796 (13.3%) 2372 (13.1%)  
Region     0.999 
  Asia 918 (15.3%) 929 (15.3%) 926 (15.4%) 2773 (15.4%)  
  Central Europe 703 (11.7%) 704 (11.6%) 706 (11.8%) 2113 (11.7%)  
  Latin America 319 (5.3%) 319 (5.3%) 316 (5.3%) 954 (5.3%)  
  USA, Canada 2150 (35.9%) 2195 (36.2%) 2152 (35.9%) 6497 (36.0%)  
  Western Europe 1541 (25.8%) 1552 (25.6%) 1543 (25.7%) 4636 (25.7%)  
  Other 352 (5.9%) 360 (5.9%) 355 (5.9%) 1067 (5.9%)  
AF Type     0.104 
  Paroxysmal 1916 (32.0%) 1974 (32.6%) 2030 (33.9%) 5920 (32.8%)  
  Permanent 2123 (35.5%) 2183 (36.0%) 2045 (34.1%) 6351 (35.2%)  
  Persistent 1941 (32.5%) 1901 (31.4%) 1922 (32.0%) 5764 (32.0%)  
Aspirin at baseline     0.086 
 2384 (39.8%) 2338 (38.6%) 2431 (40.5%) 7153 (39.7%)  
CHADS2 Score     0.666 
  Mean ± SD 2.1 ± 1.1 2.2 ± 1.1 2.1 ± 1.1 2.1 ± 1.1  
  Median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)  
CHADS2 Score     0.221 







Treatment Pattern Label Total 
     P-
Value 
Dabigatran 110mg BID 
n = 5983 
Dabigatran 150mg BID 
n = 6059 
Warfarin 
n = 5998 n = 18040 
  1 1797 (30.0%) 1810 (29.9%) 1705 (28.4%) 5312 (29.4%)  
  2 2081 (34.8%) 2129 (35.1%) 2212 (36.9%) 6422 (35.6%)  
  3+ 1954 (32.7%) 1975 (32.6%) 1926 (32.1%) 5855 (32.5%)  
History of Heart Failure     0.889 
 1929 (32.2%) 1930 (31.9%) 1915 (31.9%) 5774 (32.0%)  
Baseline Heart Failure 
Classification 
    0.268 
  NYHA I 293 (15.2%) 292 (15.1%) 295 (15.4%) 880 (15.3%)  
  NYHA II 1222 (63.4%) 1195 (62.0%) 1219 (63.7%) 3636 (63.0%)  
  NYHA III 383 (19.9%) 400 (20.7%) 352 (18.4%) 1135 (19.7%)  
  NYHA IV 30 (1.6%) 41 (2.1%) 48 (2.5%) 119 (2.1%)  
LVEF     0.723 
  <=40% 647 (22.0%) 651 (21.9%) 628 (21.2%) 1926 (21.7%)  
Baseline Hypertension  
Requiring Medical Treatment 
    0.974 
 4711 (78.7%) 4781 (78.9%) 4729 (78.8%) 14221 (78.8%)  
History of Diabetes Mellitus     0.872 
 1401 (23.4%) 1398 (23.1%) 1405 (23.4%) 4204 (23.3%)  
History of Stroke/Systemic 
Embolism/TIA 
    0.389 
 1302 (21.8%) 1357 (22.4%) 1282 (21.4%) 3941 (21.8%)  
Baseline Creatinine 
Clearance [mL/min] 
    0.846 
  Mean ± SD 73.0 ± 27.7 72.8 ± 28.2 73.0 ± 27.4 72.9 ± 27.8  
  Median (IQR) 68.7 (53.2, 87.2) 67.9 (53.0, 86.4) 68.5 (53.8, 86.6) 68.4 (53.4, 86.8)  
Creatinine Clearance     0.044 
  <30 14 (0.2%) 31 (0.5%) 29 (0.5%) 74 (0.4%)  
  30<= and <50 1127 (19.7%) 1152 (19.7%) 1048 (18.2%) 3327 (19.2%)  
  50<= and <80 2705 (47.2%) 2770 (47.5%) 2794 (48.7%) 8269 (47.8%)  
  >=80 1889 (32.9%) 1880 (32.2%) 1872 (32.6%) 5641 (32.6%)  
Weight [kg]     0.385 
  Mean ± SD 82.9 ± 19.9 82.4 ± 19.3 82.6 ± 19.6 82.7 ± 19.6  
  Median (IQR) 80.5 (70.0, 94.0) 80.0 (69.0, 93.0) 80.0 (70.0, 93.0) 80.0 (69.9, 93.4)  
Continuous variables compared using one-way analysis of variance. 






As seen in Table 2, patients who took warfarin had the highest rate of stroke (2.1%) and 
major bleeding (4.7%). Patients who took dabigatran 150mg had the lowest risk of stroke 
(0.9%), and patients who took dabigatran 110mg had the lowest rate of major bleeding 
(3.6%). 
 
Table 2: Outcomes 
  Treatment Pattern Label Total      P-Value 
 
Dabigatran 110mg bid 
n = 5983 
Dabigatran 150mg bid 
n = 6059 
Warfarin 
n = 5998 n = 18040  
Stroke/Systemic Embolism     < 0.001 
 84 (1.4%) 53 (0.9%) 125 (2.1%) 262 (1.5%)  
Major Bleeding     0.011 
 216 (3.6%) 261 (4.3%) 281 (4.7%) 758 (4.2%)  
 
 
To build the predictive risk models for ischemic stroke or systemic embolism and major 
bleeding, we used prior literature and clinical expertise, to choose 15 variables that could 
contribute to the risk of stroke or systemic embolism, and 16 variables that could 
contribute to the risk of major bleeding. We then conducted two multivariate logistic 
regressions using all of these 15 variables for stroke and 16 variables for major bleeding. 










Table 3-A: Logistic Full Model: Stroke or Systemic Embolism  
 




Square Pr > ChiSq 
Treatment Pattern 2 9.5803 0.0083 
Age 1 0.0413 0.8389 
Weight 1 0.8192 0.3654 
Sex 1 0.9691 0.3249 
Region 4 4.4377 0.3500 
Aspirin at Baseline 1 0.0236 0.8778 
AF Type 2 2.0821 0.3531 
Baseline Heart 
Failure 
1 0.8617 0.3533 
Baseline 
Hypertension 
1 1.0227 0.3119 
Baseline Diabetes 
Mellitus 




1 28.1507 <.0001 
Creatinine 
Clearance 
1 6.3709 0.0116 
Age * Treatment 
Pattern 


















Table 3-B: Logistic Full Model: Major Bleeding 
 
Type 3 Analysis of Effects 
Effect DF 
Wald 
Chi-Square Pr > ChiSq 
Treatment 
Pattern 
2 27.7766 <.0001 
Age 1 1.0372 0.3085 
Weight 1 0.7499 0.3865 
Sex 1 1.5558 0.2123 
Region 4 54.7331 <.0001 
Aspirin at 
Baseline 
1 8.3936 0.0038 
AF Type 2 3.7635 0.1523 
Baseline Heart 
Failure 
1 0.5020 0.4786 
Baseline 
Hypertension 
1 1.6975 0.1926 
Baseline Diabetes 
Mellitus 




1 4.9456 0.0262 
Creatinine 
Clearance 
1 36.0031 <.0001 
Age * Treatment 
Pattern 




2 14.1518 0.0008 
Treatment 
Pattern * AF 
Type 












To create the final predictive risk models, we used the Harrell Backwards Selection 
Strategy for each model, to sequentially remove the variable that had the smallest 
contribution to the model’s predictive capacity. After the removal of each variable, the 
model was run again, and the process was repeated until all variables had a p value of less 
than 0.2. Through this process, 6 variables were removed from the stroke or systemic 
embolism model (Weight, Sex, Aspirin at Baseline, AF Type, Baseline Heart Failure, 
Baseline Hypertension) and 2 variables were removed from the major bleeding model 
(Sex, Baseline Hypertension). Tables 4-A and 4-B show the analysis of effects of the 9 
variables included in the final stroke or systemic embolism risk model, and the 14 
variables included in the final major bleeding risk model. 
 
Table 4-A: Logistic Prediction Model: Stroke or Systemic Embolism 
 




Square Pr > ChiSq 
Treatment 
Pattern 
2 9.3071 0.0095 
Age 1 0.0128 0.9098 
Region 4 7.0768 0.1319 
Baseline Diabetes 
Mellitus 




1 27.7175 <.0001 
Creatinine 
Clearance 
1 9.8821 0.0017 
Age * Treatment 
Pattern 




















2 9.6253 0.0081 
 
 
Table 4-B: Logistic Prediction Model: Major Bleeding 




Square Pr > ChiSq 
Treatment 
Pattern 
2 27.5394 <.0001 
Age 1 1.0161 0.3135 
Weight 1 1.6399 0.2003 
Region 4 54.7754 <.0001 
Aspirin at 
Baseline 
1 8.9961 0.0027 
AF Type 2 3.9765 0.1369 
Baseline Heart 
Failure 
1 0.4419 0.5062 
Baseline Diabetes 
Mellitus 




1 4.9358 0.0263 
Creatinine 
Clearance 
1 37.2981 <.0001 
Age * Treatment 
Pattern 














2 14.0595 0.0009 
Treatment 
Pattern * AF 
Type 





2 5.3254 0.0698 
 
 
Figures 1-A and 1-B demonstrate the impact of individual patient variables on the full 
stroke or systemic embolism and major bleeding models respectively. For the stroke or 
systemic embolism model, a history of stroke/systemic embolism/TIA (OR 2.01) and 
baseline diabetes with warfarin (OR 2.00) had the largest impact on risk of stroke or 
systemic embolism. Age in warfarin (OR 1.03), and whether the patient was taking 


















For the major bleeding model, history of heart failure in patients taking dabigatran 110mg 
(OR 1.52), Central Europe versus USA, Canada (OR 0.46), and age in dabigatran 150mg 
(OR 1.93) had the greatest impact on the risk of bleeding. History of heart failure in 
dabigatran 150mg (OR 0.96) and weight in warfarin (OR 1.04) had the smallest impact 
on the model. 
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The final multivariate predictive risk models for stroke or systemic embolism and major 
bleeding are presented in Tables 5-A and 5-B. The estimates for stroke or systemic 
embolism show the value of the intercept at -3.3677, and the estimates for major bleeding 
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show the value of the intercept at -2.8732. The Tables also show the estimates of the 
regression coefficients for each variable included in the final stroke model or bleeding 
model. Using these models, the risk of stroke or systemic embolism and the risk of major 
bleeding can be calculated for any patient based on the equation Y (risk) = b0 + X1b1 + 
X2b2 + X3b3 + X4b4, where b0 is the model’s intercept, b1-4 are the model’s regression 
coefficients, and X1-4 are the variables, defined as either 0 or 1 based on the absence or 
presence of the variable. 
 
 Table 5-A: Logistic Prediction Model: Stroke or Systemic Embolism 
 
Analysis of Penalized Maximum Likelihood Estimates 





Square Pr > ChiSq 
Intercept  1 -3.3677 1.2175 7.6507 0.0057 
Treatment Pattern A 1 0.6235 1.7072 0.1334 0.7150 
Treatment Pattern B 1 -5.9296 2.1931 7.3100 0.0069 
Age  1 0.00154 0.0136 0.0128 0.9098 
Region Asia 1 0.4461 0.1831 5.9386 0.0148 
Region Central Europe 1 -0.0432 0.2414 0.0321 0.8579 
Region Latin, Other 1 0.1238 0.2175 0.3241 0.5691 
Region Western Europe 1 0.1419 0.1706 0.6924 0.4053 
Baseline Diabetes 
Mellitus 




 1 0.6961 0.1322 27.7175 <.0001 
Creatinine 
Clearance 
 1 -0.0157 0.00498 9.8821 0.0017 
Age * Treatment 
Pattern 
A 1 -0.0164 0.0196 0.6982 0.4034 
Age * Treatment 
Pattern 










Analysis of Penalized Maximum Likelihood Estimates 





















Table 5-B: Logistic Prediction Model: Major Bleeding 
 
Analysis of Penalized Maximum Likelihood Estimates 





Square Pr > ChiSq 
Intercept   1 -2.8732 0.8338 11.8757 0.0006 
Treatment Pattern A  1 -3.8326 1.1614 10.8894 0.0010 
Treatment Pattern B  1 -5.9535 1.1736 25.7353 <.0001 
Age   1 0.00922 0.00915 1.0161 0.3135 
Weight   1 0.00504 0.00393 1.6399 0.2003 
Region Asia  1 -0.4659 0.1383 11.3387 0.0008 
Region Central 
Europe 
 1 -0.7622 0.1589 23.0209 <.0001 
Region Latin, 
Other 
 1 -0.6145 0.1367 20.1987 <.0001 
Region Western 
Europe 
 1 -0.5979 0.1054 32.1737 <.0001 
Aspirin at Baseline   1 0.2334 0.0778 8.9961 0.0027 
AF Type Paroxysmal  1 -0.2440 0.1553 2.4680 0.1162 
AF Type Permanent  1 0.0521 0.1512 0.1188 0.7303 
Baseline Heart Failure   1 0.0919 0.1383 0.4419 0.5062 
Baseline Diabetes 
Mellitus 
  1 0.2951 0.0860 11.7785 0.0006 
Baseline 
Stroke/Embolus/TIA 






Analysis of Penalized Maximum Likelihood Estimates 





Square Pr > ChiSq 
Creatinine Clearance   1 -0.0152 0.00248 37.2981 <.0001 
Age*Treatment 
Pattern 
A  1 0.0353 0.0131 7.2561 0.0071 
Age*Treatment 
Pattern 
B  1 0.0560 0.0130 18.4606 <.0001 
Weight * Treatment 
Pattern 
A  1 0.00834 0.00495 2.8309 0.0925 
Weight * Treatment 
Pattern 
B  1 0.0185 0.00493 14.0500 0.0002 
Treatment Pattern * 
AF Type 
A Paroxysmal 1 0.4333 0.2319 3.4917 0.0617 
Treatment Pattern * 
AF Type 
A Permanent 1 -0.0351 0.2329 0.0227 0.8802 
Treatment Pattern * 
AF Type 
B Paroxysmal 1 0.4418 0.2233 3.9148 0.0479 
Treatment Pattern * 
AF Type 
B Permanent 1 0.1102 0.2217 0.2470 0.6192 
Baseline Heart Failure 
* Treatment Pattern 
A  1 0.3297 0.2025 2.6516 0.1034 
Baseline Heart Failure 
* Treatment Pattern 
B  1 -0.1417 0.2012 0.4962 0.4812 
 
The models were tested using a bootstrapping procedure, in which the predictive model 
was applied to a randomly selected subset of patients, and the model’s output, including 
the predicted risk of stroke, was then compared to the true results of the entire population. 
This procedure was repeated 10 times, to examine the true predictive capacity of each 
model. To examine the predicted events with the bootstrapped population compared to 
the true events of the population, the predicted events of the bootstrapped population 
were calibrated to the true events of the full RE-LY sample population. Tables 6-A and 6-






the stroke or systemic embolism model and 0.98247 for the major bleeding model, with 
Pr > |t| values < .001. These results demonstrate that we can reject the null hypothesis that 
the slope of the model is 0. Tables 7-A and 7-B show the test slope results with Pr>F 
values of 0.8311 and 0.7318 for the stroke or systemic embolism model and major 
bleeding model respectively, demonstrating that we cannot reject the null hypothesis that 
the slope is 1. The proximity of the slope to 1, is demonstrated by the R-square values of 
0.9560 for the stroke or systemic embolism model, and 0.9802 for the major bleeding 
model. The proximity of the slope to 1 demonstrates the strength of the model’s 
predictive capacity. The calibration is demonstrated graphically in Figures 2-A and 2-B, 
with each event rate for each bootstrap sample against its respective population. The 
proximity of the intercept towards 0 and the R-Square to 1, and the proximity of the 
calibration graph to the 45-degree line, demonstrate the linearity of the calibration and 
therefore the predictive strength of the model. The c-statistic, or area under the curve, is 























Error t Value Pr > |t| 
Intercept 1 -0.00022276 0.00136 -0.16 0.8743 
Slope 1 0.98356 0.07458 13.19 <.0001 
 
 
Table 6-B: Major Bleeding Prediction Model Calibration 
 





Error t Value Pr > |t| 
Intercept 1 0.00009327 0.00255 0.04 0.9718 
Mean 1 0.98247 0.04938 19.90 <.0001 
 
Table 7-A: Stroke or Systemic Embolism Prediction Model Calibration 
Test Slope Results for Stroke or Systemic Embolism 
Source DF 
Mean 
Square F Value Pr > F 
Numerator 1 2.833789E-7 0.05 0.8311 




Table 7-B: Major Bleeding Prediction Model Calibration 





Value Pr > F 
Numerator 1 0.00000251 0.13 0.7318 
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We then applied the predictive risk model to each patient in the RE-LY trial to assess for 
heterogeneity of treatment effect of both dabigatran 110mg and 150mg versus warfarin. 
The following tables show the number of patients who had a statistically significant 
difference between their stroke or systemic embolism, or major bleeding risk with 
dabigatran or warfarin. As seen in Tables 8-A and 8-B, 30.37% and 46.45% of patients 
had statistically significant differences in their risk of stroke or systemic embolism and 
major bleeding, respectively, with dabigatran 110mg versus warfarin. As seen in Tables 
9-A and 9-B, 70.88% and 47.58% of patients had statistically significant differences in 
stroke or systemic embolism and major bleeding risk, respectively, with dabigatran 
150mg versus Warfarin. 
 
Table 8-A 
Stroke/Systemic Embolism log(odds): Dabigatran 110mg - 
Warfarin Significance 







12562 69.63 12562 69.63 
Significant 5478 30.37 18040 100.00 
 
Table 8-B 
Major Bleeding log(odds): Dabigatran 110mg - Warfarin 
Significance 







9661 53.55 9661 53.55 








Stroke/Systemic Embolism log(odds): Dabigatran 150mg - 
Warfarin Significance 







5254 29.12 5254 29.12 
Significant 12786 70.88 18040 100.00 
 
Table 9-B 
Major Bleeding log(odds): Dabigatran 150mg - Warfarin 
Significance 







9457 52.42 9457 52.42 
Significant 8583 47.58 18040 100.00 
 
 
It is important to note however, that the frequency of patients who had a statistically 
significantly different risk with dabigatran versus warfarin, includes both patients with an 
increased risk and patients with a decreased risk. Figures 3 and 4 demonstrate the 
distribution of this risk, distinguishing patients with and without a statistically significant 
difference by color and distance from the fit line, and by whether they had an increased 
or decreased risk, by position above or below the fit line, respectively, with dabigatran. In 
Figure 3-A for example, all patients who had a statistically significant risk of stroke or 
systemic embolism with dabigatran 110mg, had a decreased risk. With regard to bleeding 
risk in Figure 3-B however, while most patients had a decreased risk with dabigatran 






and decreased risk is seen in Figure 4-B, which demonstrates that many patients had a 
decreased risk of bleeding with dabigatran 150mg, and many patients that had an 
increased risk of bleeding.  
 
Figures 3A-3B: Dabigatran 110mg - Warfarin Significance 
                           Figure 3-A                                                         Figure 3-B 
                                      
                                
     Figures 4A-4B: Dabigatran 150mg - Warfarin Significance 
   Figure 4-A                                                           Figure 4-B 
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To further examine the heterogeneity of treatment effect, we put each patient through the 
model to determine their risk of stroke or systemic embolism and risk of major bleeding 
with dabigatran 110mg, dabigatran 150mg, and warfarin. We then calculated the 
differences in these risks as risk of stroke or systemic embolism with dabigatran minus 
risk of stroke or systemic embolism with warfarin, and risk of major bleeding with 
dabigatran minus risk of major bleeding with warfarin. As seen in Table 10, the mean 
difference of risk between dabigatran 110 and Warfarin was -0.78% ± 0.95% for stroke 
or systemic embolism and -1.12% ± 1.44% for major bleeding. The mean difference of 
risk between dabigatran 150mg was -1.32% ± 1.31% for stroke or systemic embolism 
and -0.41% ± 2.39% for major bleeding. These ranges of risk differences for dabigatran 
110mg and 150mg versus warfarin are demonstrated graphically in Figures 5-6. All areas 
of the curves to the left of 0, represent those patients with a smaller risk of stroke or 
systemic embolism, or major bleeding with dabigatran, and all areas to the right of the 
curves represent those patients with a smaller risk of stroke or systemic embolism or 
major bleeding risk with warfarin. The fact that all curves cross the zero line 
demonstrates the range of treatment superiority with regard to a given risk. The width of 
the curves, particularly with regard to major bleeding demonstrates the range of benefits 















Difference of: N Mean Std Dev Minimum Maximum 
STROKSE: 
Dabigatran 110mg - 
Warfarin 
17237 -0.0077530 0.0095157 -0.0932936 0.0215243 
Major Bleeding: 
Dabigatran 110mg - 
Warfarin 
17226 -0.0112073 0.0143663 -0.0776957 0.2324420 
STROKSE: 
Dabigatran 150mg - 
Warfarin 
17237 -0.0131816 0.0131320 -0.1156282 0.0329962 
Major Bleeding: 
Dabigatran 150mg - 
Warfarin 




























To determine the range of patients for whom dabigatran 110mg or dabigatran 150mg 
would be superior to warfarin, regarding the risk of stroke or systemic embolism and 
major bleeding, we plotted the all patients’ risk on a chart with a two axes chart, one for 
each risk (Figures 7 and 8). The X-axis is defined as risk of stroke or systemic embolism 
with dabigatran minus risk of stroke or systemic embolism with warfarin, and therefore, 
all patients who fall below the zero line, have a lower risk of stroke or systemic embolism 
with dabigatran, and those who fall above the zero line have a lower risk of stroke or 
systemic embolism with warfarin. The Y-axis is defined as risk of major bleeding with 
dabigatran minus risk of stroke or systemic embolism with warfarin, and therefore all 
patients who fall to the left of the zero line, have a lower risk of major bleeding with 
dabigatran, and those who fall to the right of the zero line, have higher risk of major 


















of the chart would benefit from dabigatran relative to warfarin, as their risk of stroke or 
systemic embolism and major bleeding are both lower with dabigatran. Those patients 
who fall in the upper right quadrant of the chart would benefit from warfarin relative to 
dabigatran, as their risk of stroke or systemic embolism and major bleeding are both 
lower with warfarin. However, in the upper left and lower right quadrants, there are 
decisional conflicts. The patients in the upper left-hand corner have a lower risk of stroke 
with warfarin, but a lower risk of bleeding with dabigatran. The patients in the lower 
right-hand corner have a lower risk of stroke with dabigatran, but a lower risk of bleeding 
with warfarin. For those a lower these patients in the upper-left, and lower-right hand 
corners of the chart, treatment decisions could be made via a well-informed shared-
decision-making process, taking into account patients’ concerns, values and differences 
in risk-tolerance between stroke or systemic embolism or major bleeding. 
 
Figures 7 and 8 show that for dabigatran 110mg and 150mg versus Warfarin, there are 
patients whose stroke or systemic embolism and major bleeding risk combinations fall in 
all four classifications. The most notable difference between the two figures is that 
dabigatran 150mg figure has many more patients with a lower risk of bleeding with 
warfarin, thus explaining why this figure has so many patients who fall in the upper right 
quadrant where patients have both a lower stroke or systemic embolism and major 






















In this analysis, we used data from the RE-LY trial to develop two multivariate risk 
models to predict patients’ risk of stroke or systemic embolism, and risk of major 
bleeding, with treatment with warfarin, dabigatran 110mg and dabigatran 150mg. We 
applied these risk models to each patient in the RE-LY trial, found significant 
heterogeneity among patients in the benefits and risks of using the three different 
medications. For example, some patients derive a much greater benefit than others in 
stroke or systemic embolism risk reduction from using dabigatran 110mg versus 
warfarin. And other patients derive a much greater risk than others in major hemorrhage 
when using dabigatran 150mg compared to warfarin. The range of this heterogeneity of 
treatment effect is demonstrated by Table 8 and figures 6-7, which show the distribution 
of the differences in absolute risk reduction for each patient when using dabigatran 
150mg and dabigatran 110mg versus warfarin. The mean difference (dabigatran minus 
warfarin) in the risk of stroke was -0.78% ± 0.95% for dabigatran 110mg and -1.32% ± 
1.31% for dabigatran 150mg. The mean difference in the risk of major bleeding was -
1.12% ± 1.44% for dabigatran 110mg and -0.41% ± 2.39% for dabigatran 150mg. These 
findings confirm our hypothesis that there is a heterogeneity of treatment effect with 
regard to dabigatran and warfarin.  
 
The heterogeneity of treatment effect was explained by Figures 2-A and 2-B, which show 
the contributions of individual characteristics to the risk of stroke or major bleeding. 






or systemic embolism or major bleeding, respectively. Whereas other variables, such as 
male gender or region decreased the risk of stroke or systemic embolism or major 
bleeding, respectively. These opposing risk factors, with their different weight, can 
complicate clinical decision making, and highlight the need for multivariate prediction 
models to accurately and objectively weigh individual risks and benefits. 
 
These findings build on recent studies to demonstrate the importance of analyzing clinical 
trials for heterogeneity of treatment effect using multivariate risk models.  Salisbury et 
demonstrate the heterogeneity of treatment effect between clopidogrel and prasugrel in 
the TRITON-TIMI 38 trial, and by Kernan et al to demonstrate the heterogeneity of 
treatment of pioglitazone post stroke or TIA in the IRIS trial (11,12). Our application of 
multivariate risk models to the RE-LY trial similarly found heterogeneity of treatment 
effect, that was previously unknown, adding to further evidence regarding the potential 
benefit of multivariate predictive risk models to clinical care.  
 
To assess the potential impact of these findings, it is important to return to the current 
state of clinical practice and decision making with regard to dabigatran and warfarin. In 
the U.S. clinicians and patients choose between doses of dabigatran 150mg and 75mg and 
warfarin based on the findings of clinical trials such as RE-LY, and their respective 
subgroup analyses. However, while the findings of these trials report means, medians, 
standard deviations and the results that are best for the population as whole, they don’t 
necessarily reflect the results for patients at the extremes of the treatment effect. For 






risks of major bleeding with dabigatran 150mg versus warfarin warfarin (15). Our 
analysis does not dispute this finding, but rather notes that for certain patients there is a 
significantly increased risk of bleeding with dabigatran 150mg compared to warfarin.  
 
Trials such as RE-LY do publish subgroup analyses to account for this heterogeneity of 
treatment effect. However, these subgroup analyses have numerous statistical limitations, 
can pose opposing risk contributions from the application of different subgroups, and are 
not easy for a clinician to practically apply to individual patients in the clinical setting. 
Furthermore, while these subgroup analyses certainly narrow the population to the 
individual, they still generalize results to a population that shares only one characteristics. 
This is akin to Netflix recommending a movie to a 70-year-old woman, because that 
movie has been popular among people over the age of 65. Much like Netflix is able to 
make a movie prediction to this woman based on her age, gender, the time it takes her to 
finish a TV show, and the actresses in previous shows she has finished, modern medicine 
has the potential to make individualized medication recommendations based on multiple 
individual characteristics.  
 
Most importantly, our findings that there are both patients for whom dabigatran or 
warfarin would reduce their risk of stroke and bleeding, demonstrates the potential for 
more individualized decisions to improve patient health. These data are displayed 
graphically in figures 7 and 8 showing each patients risk along two axes, for risk of 
stroke and risk of major bleeding. Those patients who are in the lower left, and upper 






embolism and major hemorrhage with dabigatran and warfarin, respectively. The 
challenge in the clinical setting, is to identify which quadrant a given patient would fall 
in, such that their risk of stroke or major bleeding could be minimized. 
 
The basis of these findings in a multivariate predictive risk model, highlights the potential 
for this model to be used in clinical practice to predict patients risks of stroke or bleeding 
with dabigatran versus warfarin. Before this risk model is used clinically, it will need to 
be tested in further populations. However, if validated, it’s use in clinical practice would 
be beneficial, and feasible. Multivariate predictive risk models are already in widespread 
use, with clinicians and patients using multivariate risk scores such as CHADSVASC2 
and HASBLED to predict their individual benefits and risk with using anticoagulation. 
This multivariate predictive risk model could be used in a similar way to help clinicians 
and patients make a fully informed, individualized decision about a medication at the 
point of care.  
 
While such a tool would identify those patients who would clearly benefit from warfarin 
or dabigatran with regard to both stroke and bleeding risk, there will also be patients who 
have the lowest stroke risk with one medication, and the lowest bleeding risk with the 
other medication. These patients are represented by the upper left and lower right 
quadrants in Figures 7 and 8. These treatment decisions pose a challenge, that will require 
careful evaluation of the degree of risks and benefits with different given treatment, and a 
shared decision-making process to identify the treatment that would best align with 






To facilitate the decision-making around treatments that carry both a benefit and a risk 
with regard to other available treatments, Salisbury et al, proposed the calculation of a 
“net clinical benefit score” (11). The net clinical benefit is defined as the benefit to risk 
ratio. As applied to our findings, net clinical benefit would be defined as the ratio of the 
reduction of risk in stroke or systemic embolism (the benefit), to the increase in risk of 
bleeding. For each patient, the benefit of a given treatment, or reduction in risk of stroke 
or systemic embolism, would be calculated as the absolute difference of the predicted risk 
of stroke or systemic embolism for warfarin minus the predicted risk with dabigatran. 
The risk, or increased risk of major hemorrhage, would be calculated as the absolute 
difference of the predicted risk of major hemorrhage with warfarin minus the predicted 
risk with dabigatran. For each patient a benefit to risk ratio >1, or an absolute benefit with 
dabigatran that is greater than the absolute risk with dabigatran, would signify a net 
benefit with dabigatran relative to warfarin. A ratio of <1, or an absolute benefit with 
dabigatran less than the absolute risk increase with dabigatran, indicates a net benefit 
with warfarin relative to dabigatran.  
 
In clinical practice, patients and clinicians may have their own individual perspectives on 
the amount of benefit required to outweigh a given risk. For example, some patients and 
clinicians might feel that preventing stroke or systemic embolism is twice as important as 
avoiding major hemorrhage, while others might feel that preventing stroke or systemic 
embolism is half as important as avoiding major hemorrhage. In the first group who put 
greater emphasis on reducing stroke, a benefit to risk ratio of >0.5 would be required to 






who put greater emphasis on avoiding hemorrhage, a benefit to risk ratio of >2 would be 
required to signify a net clinical benefit with dabigatran relative to warfarin (11). 
 
The presentation of such a net clinical benefit score could help patients and clinicians 
simplify challenging decisions. Such a tool could be part of a larger strategy to 
communicate risk in an intuitive fashion, and to facilitate the use of multivariate 






















Effective presentation of risk models to facilitate shared decision making  
 
The promise of individualized patient data, is its potential to guide clinical decision-
making. Thus, as we develop methods to provide more individualized data, we must also 
develop tools to present the data in a way that can most effectively aid decision-makers.  
 
These tools can be used as part of the shared-decision making model, which is designed 
to enhance patient clinician communication, and ensure treatment decisions that are 
backed by all available evidence, and align with patient values (20). Shared decision 
making is recommended by the American Heart Association for anticoagulant treatment 
decisions in AF, to ensure that treatment decisions are aligned with patient’s values (14). 
 
The shared decision-making model consists of a clinician and patient forming a 
partnership, through which the clinician explains the risks and benefits of different 
treatment options, patients explain their experiences, values and thoughts about different 
treatments, and together the patients and clinicians discuss their thoughts about the 
treatment options, and agree on a course forward (20-23). There is of course a range of 
the degree to which different patients wish to be involved in the decision-making process, 
and it is important for clinicians, at the outset, to ask patients what they would prefer. 
This might range from the patient seeking information and making the decision, to the 
patient asking the doctor’s opinion and then making the decision, to asking the doctor to 
make a decision by themselves (24). However, it is important that clinicians do not 






to participate in shared decision making versus usual care, report greater satisfaction 
(20,25). 
 
Visual decision aids can greatly enhance the shared decision-making process by helping 
the clinician convey treatment risk and benefit information in a clear and easy to 
understand manner (20). Effective decision-aids incorporate a number of principles that 
have been learned from behavioral decision-making science and studies of past decision 
aids. 
 
First, decision-aids should avoid use of number needed to treat statistics and relative risk 
statistics. Number needed to treat is a difficult concept for many patients to understand, 
and relative risk can lead both patients and clinicians to perceive an exaggerated risk or 
treatment effect. As an example of this phenomenon with relative risk, a patient who is 
told that a given treatment will reduce their risk of stroke by 50%, is will likely be more 
inclined to use the drug than if they were told that it reduced their risk of stroke from 2% 
to 1% (26). Furthermore, as previously discussed, a relative risk reduction of 50% may 
have significantly different implications for a patient who sees their risk decrease from 
20% to 10% versus a patient who sees their risk decrease from 2% to 1%. Therefore, in 
order to avoid an exaggeration of treatment effect, and to ensure that risks are truly 
individualized, decision-aids should present risks as absolute risks (24,27,28). 
 
In addition to presenting risks as absolute risks, it is also important for decision aids to 






a patient that they have a 5% risk of major bleeding over the next 10 years with a given 
anticoagulant, they may incorrectly assume that all of their bleeding risk is due to the 
anticoagulant, and that their risk without treatment would be 0%. Therefore, if the patient 
has a 4% baseline risk of bleeding without treatment over the course of 10 years, it is 
important to convey that information, and to explain that taking the anticoagulant will 
add 1% to their absolute risk of bleeding over 10 years (27,28). 
 
Similarly, it may be helpful to provide patients with contextual absolute risk information 
about their other health risks, as a basis of comparison for the risks associated with 
treatments. For example, if a patient is weighing whether to take a drug that is associated 
with a 1% absolute risk of bleeding over 10 years, it may be helpful for them to 
understand that their absolute risk of carotid artery disease over that same period is 40% 
(27). 
 
When comparing the absolute risks associated with multiple treatments, it is important 
for decision aids to convey those risks in consistent formats. That is, if one risk is 
presented as a percent, the other risk should be presented as a percent, not as a frequency 
ratio. People, especially with lower numeracy, which tends to decrease with age, may 
have difficulty comparing a 7% risk to a 5/100 risk, and it has been found that people 
tend to be biased, in perceiving frequencies as being greater than percents (27,29,30). 
Therefore, a 7% risk should be compared to a 5% risk, or a 7/100 risk should be 
compared to 5/100 risk. Furthermore, if the risks are presented as frequency ratios, it is 






should not be compared to a 6/75 risk with drug B. Rather, this should be presented as a 
4/100 risk with drug A, compared to an 8/100 risk with drug B. Additionally, it is best to 
avoid presenting frequencies in a “1 in x” format, as this has been found to be difficult for 
patients to understand (27,31). And, when possible, it is best to use smaller denominators. 
A 1/10 risk is found to be much better intuitively understood than a 1/100 risk (27,32). 
 
There is significant debate on the role of narrative language on decision aids. The 
generally agreed upon notion is that “words matter.” The challenge then is to determine 
when they serve to add helpful additional information, versus when they introduce or 
exacerbate anecdote bias. For example, the inclusion of patient testimonials on decision 
aids has been found to make patients more concerned about the severity of bad outcomes 
(27,33). For a patient who views a cerebral hemorrhage as akin to a bruise on their 
forehead, the inclusion of such a testimonial would be warranted. However, for the 
patient whose friend recently died of a cerebral hemorrhage, the sharing a testimonial of 
cerebral hemorrhage might further bias them to overestimate the likelihood of a 
hemorrhage in their decision-making process. In fact, one of the greatest benefits of 
visual decision-aids, is their ability to reduce anecdote bias, and allow patients and 
clinicians to consider data is as objective a way as possible, so they can make decisions in 
line with their values (27,34). 
 
Language can also be added to decision-aids in order to “label” results. For example, 
rather than only telling patients that the risk of hemorrhage is 1% with one drug and 5% 






“high.” Patients given decision aids with labels were found to be more likely to 
incorporate risk information in their decision-making (27,35). 
 
Decision-aids can introduce “framing effects” through which different presentations of 
identical information, can lead to different patient decisions. Numerous studies have 
demonstrated that patients are more likely to tolerate risky medications or procedures if 
the risks of procedures were framed in a positive as opposed to negative frame (27,36). 
For example, Levin et al, showed that people were hypothetically more willing to 
undergo a procedure with a 50% success rate than a procedure with a 50% failure rate 
(37).  This line of reasoning suggests that patients would be more inclined to take an 
anticoagulant if they are told “95% of patients with AF who take Warfarin don’t have a 
stroke within 10 years,” compared to being told that “5% of patients with AF who take 
warfarin have a stroke within 10 years.”b The presence of framing effects should not be 
used to influence patient decisions, but should be considered as potential sources of 
biases in patient decisions. 
 
The “recency effect” is another bias that can be introduced by decision aids. In this bias, 
patients are more likely to place greater emphasis on the piece of information they heard 
last (28,38). For example, if a patient is first told about an anticoagulant’s association 
with hemorrhage, and are then told about its’ effect on stroke prevention, they may place 
disproportionate weight on the drug’s impact on stroke prevention. And if they are first 
told about stroke prevention, and then told about hemorrhage, they may place greater 







emphasis on hemorrhage.c To reduce this bias, decision-aids can summarize all presented 
information, prior to the patient decision, such that the value patients place on a given 
treatment characteristic, is consistent with their own personal values and not with the 
order in which it was presented (28). 
The visual presentation of decision-aids may also influence comprehension. First, while 
the use of numbers to present statistical information, may be the best way to convey 
precise, or verbatim, information, there are many benefits to conveying information 
through pictographs. Pictographs present statistics by using different colored icons 
(usually ovals, smiley faces, or bathroom symbols) to represent the affected proportion of 
an at-risk population. For example, to convey that 3/100 people who take an 
anticoagulant get a cerebral hemorrhage within 10 years, a pictograph might display 100 
bathroom figures, and color three of them red, signifying the likelihood of cerebral 
hemorrhage. Though it has been proposed that these three red figures be spread out 
among the pictograph, to emphasize the randomness of an event occurring, it has been 
found that comprehension increases when they are grouped together (27,39). Pictographs 
can be intuitively easy to understand, and have been shown to be better than bar graphs in 
conveying “gist” knowledge. Furthermore, while the use of numbers is the most effective 
way to convey precise, or verbatim, information, pictographs are superior to pie graphs in 
conveying verbatim knowledge (28,40). 
 
The major benefit of pictographs however, is their ability to address “denominator 
neglect” (41). Through this bias, people tend to overweigh numerators, and under weigh 







denominators. For example, many people are likely to believe that a 15/100 risk is greater 
than a 2/10 risk (41). Icon arrays draw people’s eyes to the denominator, to help them 
understand the context of the numerator and to get a more accurate understanding of their 
risk. The presentation of too much information can distract patients from key points such 
as the denominator, and it is therefore essential that pictographs include only the most 
important information (28,42). 
 
In addition to “neglecting” the denominator, it is also common for people to 
misunderstand the meaning of the denominator. For example, a patient who is told they 
have a 3/100 risk of hemorrhage, may assume that every 3/100 times they take an 
anticoagulant, they can expect to get a hemorrhage, and that nearly everybody eventually 
gets a hemorrhage (27,43). Icon arrays provide a shared mental model through which 
clinicians can work with patients to ensure that they accurately understand the meaning 
of the denominator and how it relates to their individual risk. 
 
Finally, icon arrays have the potential to address neglect of a time course. Risk is defined 
as events/at risk population over a given time period. However, this time period is often 
neglected. For example, patients who are told they have a 10-year, 3/100 risk of 
hemorrhage may assume that every single year, for 10 years, 3 people out of 100 will 
suffer a hemorrhage, for a total of 30 people out of 100 at the end of 10 years. Icon arrays 
should clearly display the time course of a risk, and again, help clinicians and patients 







The use of shared decision making with decision aids increases patients’ knowledge of 
pre-treatment risk and treatment options, increases patient engagement and decreases 
decisional conflict (20,44,45). Furthermore, decision-aids that are tailored to patient’s 
individual profile have been shown to have a particularly strong positive impact on 
patient comprehension (27,46). There have also been number of studies of shared 
decision making and decision aids regarding anticoagulation in AF. While many of these 
studies were done without individual risk models and prior to non-vitamin K oral 
anticoagulants, similar to other studies of shared decision-making, they found that 
patients who underwent shared decision making, had greater understanding of treatment 
options, and decreased decisional conflict (20,47). 
 
The multivariate predictive risk models for stroke or systemic embolism and major 
bleeding developed in this analysis, if validated, could be incorporated into decision-aids 
in order to help clinicians and patients with AF and an increased risk of stroke, work 
together to make decisions about anticoagulation with dabigatran versus Warfarin. The 
following icon arrays were generated using http://www.iconarray.com, a tool developed 
by the Risk Science Center at the University of Michigan, which incorporates many of 
the lessons from the decision-aid literature, to create effective decision-aids (48). 
 
These are examples of decision-aids that could be presented to two different patients. The 
first patient is Frank, a 62-year-old, 85 kg man with diabetes, a creatinine clearance of 85 
ml/min, a history of TIA, and permanent AF, who is taking Aspirin, and has no history of 






diabetes, a creatinine clearance of 85ml/min, has persistent AF and is taking aspirin, and 
has no history of stroke, systemic embolism, TIA or heart failure. 
 
For each patient, the decision-aids show their risk of stroke with dabigatran 150mg and 
warfarin, side-by side, and below that, their risk of major bleeding with dabigatran 
150mg and warfarin, side-by side. 
 
As seen in the decision-aids, both patients face decisional challenges. Frank’s risk of 
stroke is higher with warfarin, at 3.84% than it is with dabigatran, at 0.92%. However, his 
risk of major bleeding is lower with warfarin, at 8.43% than it is with dabigatran, at 
13.1%. Maria’s risk of stroke is slightly higher, with warfarin, at 2.4% than it is with 
dabigatran, at 1.49%. However, her risk of major bleeding is much lower with warfarin, 



















Frank and Maria, could both look at these personalized decision-aids with their physician, 
as part of a regular office visit, in order to understand the different risks and benefits 
associated with an anticoagulant, and alongside other considerations such as lifestyle 
implications, could make a fully informed choice that aligns with their respective values. 
Frank might have a very active lifestyle, and given his relatively young age of 62 and his 
history of TIA, might be very concerned about a stroke causing functional limitation, and 
might be willing to accept the risk of major bleeding requiring a transfusion. In this case, 
Frank would likely choose dabigatran given that it decreases his risk of stroke by close to 
3% relative to warfarin, even though it is associated with an over 4% increased risk of 
bleeding. Maria on the other hand, at age 87, might have numerous functional limitations, 
and might be more concerned about being hospitalized for major bleeding issues than she 
is about new functional limitations from a stroke. In this case, Maria might be 
unimpressed by the approximately 1% decreased risk of stroke with dabigatran relative to 
warfarin, but might be very concerned by the nearly 14% increased risk of major 
bleeding with dabigatran and would therefore be likely to choose warfarin. In such cases 
where patients place different weight on the risks of stroke and major bleeding, a net 
clinical benefit score as discussed earlier, could also play a role in calculating for the 
patient, which treatment choice would best align with their values and preferences.  
 
Such an aid could also theoretically be interactive, and further engage patients by 
providing them an opportunity change the variables in the model. For example, Frank 
could see how his risk of stroke will change as he gets older, and Maria could see how 







It is important to note that this graphic has not been tested, and only serves to highlight 
how a pictograph decision-aid could potentially convey information from the predictive 
risk model to patients as part of their usual care. Decision-aids should be studied for 
effectiveness with regard to decisional factors such as patient comprehension, decisional 
conflict and decision comfort. 
 
While risk models can be created, and decision-aids can be built, they will only be 
valuable if patients and clinicians use them during clinical practice. Given the potential 
for numerous risk models to be developed and updated over the coming years and 
decades, it is important to build an infrastructure that provides patients and clinicians 
with the latest and most relevant risk models in an easily accessible manner. One 
potential example of such an infrastructure, would be a risk calculator that is 
automatically built in to the electronic medical record, and that quickly displays decision 
aids onto a tablet that is readily available in the exam room, or to a patient’s smartphone. 
In addition to improving awareness and accessibility of newly developed risk models, 
one of the biggest challenges to the use of shared decision making and decision aids, is 
their potential impact on clinical workflow. Studies have found that shared decision 
making can add approximately 3 minutes to a clinical encounter (20,49). While 
incorporating automated systems into electronic medical records may add some 
efficiency, it is also important that shared decision making is valued by payers and health 









This study demonstrates that there is heterogeneity of treatment effect between 
dabigatran 110mg and dabigatran 150mg versus Warfarin for the RE-LY population. 
These findings were demonstrated through a multivariate predictive risk model that has 
the potential to be used in clinical practice to predict treatment effect. However, prior to 
use in clinical practice, the effectiveness predictive risk model will need to be evaluated 
against other populations. If validated, this model could enhance the shared decision-
making process by providing patients with easy-to-understand individualized information 
about their predicted risks and benefits with a given treatment. 
 
However, there are a number of limitations to our study. 
 
First, the multivariate predictive risk model has not been tested against independent 
populations outside of the RE-LY trial. To account for this limitation, we conducted a 
bootstrapping procedure, which tested the model on small samples of the RE-LY 
population against the rest of the population. However, internally validated models, due 
to the fact that they developed and tested with the same population, may be subject to 
limitations in generalizability. Thus, prior to use in clinical practice, it is important for 
this model to be tested external, independent samples. 
 
Second, the generalizability of our model is limited by the inclusion and exclusion 






an increased risk of stroke. Patients who were pregnant, had active liver disease, a 
creatinine clearance below 30 ml/min, or had a severe heart valve disorder were excluded 
from the study. However, the RE-LY trial population was designed to include those 
patients most likely to face a treatment decision of dabigatran versus warfarin, and 
despite the limitations of the inclusion and exclusion criteria, the model designed in this 
study should still have widespread clinical applicability. 
 
Third, the c-statistic, or area under the curve of our model, was only is 0.675 for the 
stroke model and 0.694 for the major bleeding model. These c-statistics represent some 
limitation in the degree of discrimination of the model and its ability to predict events 
versus non-events. However, as noted by Salisbury et al, predictive models with modest 
c-statistics are superior to the generalization of findings across a broad population, and 
models with c-statistics greater than 0.60 have been shown to be effective (4,11). 
 
Last, the models in this study only predict individualized risk for stroke and systemic 
embolism, and major bleeding. Patients may also be interested in other individualized 
information, such as their risk of myocardial infarction with each treatment option, or 
lifestyle implications of each medication. However, stroke and systemic embolism and 
major bleeding were selected for this study, because they are generally seen as the 
biggest risk and benefit concerns of anticoagulant choice in patients with AF and an 
increased risk of stroke. And these individualized risks do not need to be used in 
isolation, but rather as information alongside other considerations such as lifestyle 






Despite these limitations, this analysis shows that heterogeneity of treatment effect exists 
in the RE-LY trial, building on evidence that it exists in other trials. The multivariate 
model developed in this study demonstrates the potential of this model, if further 
validated, to be used in clinical practice to help patients understand their individualized 
risk and benefit with regard to taking warfarin or different doses of dabigatran.  
 
The increasing amount of data available in medicine poses a potential for unique 
statistical profiles to be developed for patients, such that they can make individualized 
decisions to maximize their benefits, minimize their risks and improve their health. The 
use of multivariate predictive risk models, such as that published in this analysis, have the 
potential to move clinical practice closer to this goal of precision medicine. 
 
But for multivariate predictive risk models to be used effectively in clinical practice, their 
findings must be clearly communicated and easily understood. In addition to recognizing 
the potential of unique statistical profiles to help batters hit a baseball, Ted Williams 
communicated this potentially complicated concept through a simple illustration of the 
strike zone that could be intuitively understood by boys and girls across cultures and 
generations. Using the science behind visual decision aids and effective presentation of 
statistics, we too can work to ensure that it is just as intuitive for a patient and clinician to 
use a risk model to choose between dabigatran and warfarin, as it was for a young 
baseball hitter to use Ted Williams’ strike zone graphic to choose “a good ball to hit” (1). 
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